JP2015515496A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515496A5 JP2015515496A5 JP2015509192A JP2015509192A JP2015515496A5 JP 2015515496 A5 JP2015515496 A5 JP 2015515496A5 JP 2015509192 A JP2015509192 A JP 2015509192A JP 2015509192 A JP2015509192 A JP 2015509192A JP 2015515496 A5 JP2015515496 A5 JP 2015515496A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 19
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 108010021592 Pantothenate kinase Proteins 0.000 claims description 7
- 102100024122 Pantothenate kinase 1 Human genes 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 230000006764 neuronal dysfunction Effects 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- -1 1H-indol-3-yl-methyl Chemical group 0.000 claims description 2
- 206010008748 Chorea Diseases 0.000 claims description 2
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 2
- 206010010904 Convulsion Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000010428 Muscle Weakness Diseases 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 208000012601 choreatic disease Diseases 0.000 claims description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005516 coenzyme A Substances 0.000 claims description 2
- 229940093530 coenzyme a Drugs 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 claims description 2
- 230000003955 neuronal function Effects 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- 230000007426 neuronal cell dysfunction Effects 0.000 claims 3
- 208000009017 Athetosis Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 claims 1
- 230000005494 condensation Effects 0.000 claims 1
- 238000009833 condensation Methods 0.000 claims 1
- 229940014662 pantothenate Drugs 0.000 claims 1
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 5
- 229940055726 pantothenic acid Drugs 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000000865 phosphorylative effect Effects 0.000 description 3
- 238000007309 Fischer-Speier esterification reaction Methods 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- XHFVGHPGDLDEQO-ZETCQYMHSA-N (R)-4'-phosphopantothenic acid Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O XHFVGHPGDLDEQO-ZETCQYMHSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639602P | 2012-04-27 | 2012-04-27 | |
| US61/639,602 | 2012-04-27 | ||
| PCT/US2013/038458 WO2013163576A1 (en) | 2012-04-27 | 2013-04-26 | Pantothenate derivatives for the treatment of neurologic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017055792A Division JP6560284B2 (ja) | 2012-04-27 | 2017-03-22 | 神経系の障害の処置のためのパントテン酸誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515496A JP2015515496A (ja) | 2015-05-28 |
| JP2015515496A5 true JP2015515496A5 (enExample) | 2016-06-16 |
| JP6254151B2 JP6254151B2 (ja) | 2017-12-27 |
Family
ID=48428654
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509192A Expired - Fee Related JP6254151B2 (ja) | 2012-04-27 | 2013-04-26 | 神経系の障害の処置のためのパントテン酸誘導体 |
| JP2017055792A Expired - Fee Related JP6560284B2 (ja) | 2012-04-27 | 2017-03-22 | 神経系の障害の処置のためのパントテン酸誘導体 |
| JP2019132651A Pending JP2019206553A (ja) | 2012-04-27 | 2019-07-18 | 神経系の障害の処置のためのパントテン酸誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017055792A Expired - Fee Related JP6560284B2 (ja) | 2012-04-27 | 2017-03-22 | 神経系の障害の処置のためのパントテン酸誘導体 |
| JP2019132651A Pending JP2019206553A (ja) | 2012-04-27 | 2019-07-18 | 神経系の障害の処置のためのパントテン酸誘導体 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8673883B2 (enExample) |
| EP (3) | EP3489248A1 (enExample) |
| JP (3) | JP6254151B2 (enExample) |
| KR (1) | KR20150035550A (enExample) |
| CN (2) | CN106977544B (enExample) |
| AU (3) | AU2013251345B2 (enExample) |
| BR (1) | BR112014026817A2 (enExample) |
| CA (1) | CA2879314A1 (enExample) |
| CY (2) | CY1118198T1 (enExample) |
| DK (2) | DK2841438T3 (enExample) |
| ES (2) | ES2600179T3 (enExample) |
| HR (2) | HRP20161389T1 (enExample) |
| HU (2) | HUE042199T2 (enExample) |
| IN (1) | IN2014DN09584A (enExample) |
| LT (2) | LT2841438T (enExample) |
| MX (1) | MX360149B (enExample) |
| PL (2) | PL2841438T3 (enExample) |
| PT (2) | PT3112372T (enExample) |
| RS (2) | RS58336B1 (enExample) |
| RU (2) | RU2018112720A (enExample) |
| SI (2) | SI3112372T1 (enExample) |
| SM (2) | SMT201900007T1 (enExample) |
| TR (1) | TR201819263T4 (enExample) |
| WO (1) | WO2013163576A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042199T2 (hu) * | 2012-04-27 | 2019-06-28 | Retrophin Inc | Pantotenát-származékok neurológiai rendellenességek kezelésére |
| WO2015061792A1 (en) | 2013-10-25 | 2015-04-30 | Retrophin, Inc. | Panothenate derivatives for the treatment of neurological disorders |
| EP2868662A1 (en) * | 2013-11-04 | 2015-05-06 | Acies Bio d.o.o. | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds |
| CA3007063A1 (en) * | 2015-12-08 | 2017-06-15 | Retrophin, Inc. | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders |
| US20200121604A1 (en) * | 2017-02-07 | 2020-04-23 | Retrophin, Inc. | Solid fosmetpantotenate formulations |
| US11746087B1 (en) | 2022-03-18 | 2023-09-05 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2676976A (en) | 1950-12-04 | 1954-04-27 | Nat Res Dev | Synthesis of pantothenic acid-4' phosphate |
| US2870188A (en) | 1955-10-03 | 1959-01-20 | Hoffmann La Roche | Process for the manufacture of pantothenic acid 4'-phosphate and its salts |
| RU2002110463A (ru) * | 1999-09-21 | 2004-02-27 | Басф Акциенгезелльшафт (De) | Способ и микроорганизмы для получения пантосоединений |
| WO2003008626A2 (en) | 2001-07-20 | 2003-01-30 | Oregon Health And Science University | Novel human nucleic acids encoding a pantothenate kinase and methods of use |
| EP1520030B1 (en) * | 2002-07-03 | 2011-10-26 | Basf Se | Microorganisms and processes for enhanced production of pantothenate |
| CA2618335C (en) | 2005-08-15 | 2015-03-31 | F.Hoffmann-La Roche Ag | Antiviral phosphoramidates of 4'-substituted pronucleotides |
| HUE042199T2 (hu) * | 2012-04-27 | 2019-06-28 | Retrophin Inc | Pantotenát-származékok neurológiai rendellenességek kezelésére |
-
2013
- 2013-04-26 HU HUE16001739A patent/HUE042199T2/hu unknown
- 2013-04-26 AU AU2013251345A patent/AU2013251345B2/en not_active Ceased
- 2013-04-26 LT LTEP13722201.4T patent/LT2841438T/lt unknown
- 2013-04-26 RU RU2018112720A patent/RU2018112720A/ru not_active Application Discontinuation
- 2013-04-26 WO PCT/US2013/038458 patent/WO2013163576A1/en not_active Ceased
- 2013-04-26 BR BR112014026817A patent/BR112014026817A2/pt not_active Application Discontinuation
- 2013-04-26 US US13/871,691 patent/US8673883B2/en not_active Expired - Fee Related
- 2013-04-26 TR TR2018/19263T patent/TR201819263T4/tr unknown
- 2013-04-26 RU RU2014147739A patent/RU2653497C2/ru not_active IP Right Cessation
- 2013-04-26 CN CN201611221824.7A patent/CN106977544B/zh not_active Expired - Fee Related
- 2013-04-26 MX MX2014013048A patent/MX360149B/es active IP Right Grant
- 2013-04-26 PT PT16001739T patent/PT3112372T/pt unknown
- 2013-04-26 SI SI201331263T patent/SI3112372T1/sl unknown
- 2013-04-26 EP EP18201414.2A patent/EP3489248A1/en not_active Withdrawn
- 2013-04-26 RS RS20190049A patent/RS58336B1/sr unknown
- 2013-04-26 KR KR20147033141A patent/KR20150035550A/ko not_active Abandoned
- 2013-04-26 CN CN201380033271.0A patent/CN104520307B/zh not_active Expired - Fee Related
- 2013-04-26 HU HUE13722201A patent/HUE029474T2/en unknown
- 2013-04-26 LT LTEP16001739.8T patent/LT3112372T/lt unknown
- 2013-04-26 CA CA2879314A patent/CA2879314A1/en not_active Abandoned
- 2013-04-26 JP JP2015509192A patent/JP6254151B2/ja not_active Expired - Fee Related
- 2013-04-26 DK DK13722201.4T patent/DK2841438T3/en active
- 2013-04-26 HR HRP20161389TT patent/HRP20161389T1/hr unknown
- 2013-04-26 IN IN9584DEN2014 patent/IN2014DN09584A/en unknown
- 2013-04-26 EP EP16001739.8A patent/EP3112372B1/en active Active
- 2013-04-26 SM SM20190007T patent/SMT201900007T1/it unknown
- 2013-04-26 RS RS20160939A patent/RS55319B1/sr unknown
- 2013-04-26 SI SI201330307A patent/SI2841438T1/sl unknown
- 2013-04-26 ES ES13722201.4T patent/ES2600179T3/es active Active
- 2013-04-26 PL PL13722201T patent/PL2841438T3/pl unknown
- 2013-04-26 ES ES16001739T patent/ES2708813T3/es active Active
- 2013-04-26 DK DK16001739.8T patent/DK3112372T3/en active
- 2013-04-26 EP EP13722201.4A patent/EP2841438B1/en active Active
- 2013-04-26 PT PT137222014T patent/PT2841438T/pt unknown
- 2013-04-26 PL PL16001739T patent/PL3112372T3/pl unknown
-
2014
- 2014-01-16 US US14/157,173 patent/US9181286B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 US US14/871,450 patent/US9629862B2/en not_active Expired - Fee Related
-
2016
- 2016-11-03 SM SM201600395T patent/SMT201600395B/it unknown
- 2016-11-04 CY CY20161101130T patent/CY1118198T1/el unknown
-
2017
- 2017-03-22 JP JP2017055792A patent/JP6560284B2/ja not_active Expired - Fee Related
- 2017-10-04 AU AU2017239508A patent/AU2017239508C1/en not_active Ceased
-
2019
- 2019-01-04 HR HRP20190038TT patent/HRP20190038T1/hr unknown
- 2019-02-05 CY CY20191100156T patent/CY1121238T1/el unknown
- 2019-07-18 JP JP2019132651A patent/JP2019206553A/ja active Pending
- 2019-08-20 AU AU2019219733A patent/AU2019219733A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515496A5 (enExample) | ||
| EP2010186B1 (en) | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith | |
| TW202140046A (zh) | 治療sars cov-2感染之方法 | |
| JP7025212B2 (ja) | 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法 | |
| JP2016529285A5 (enExample) | ||
| AU2017239508C1 (en) | Pantothenate derivatives for the treatment of neurologic disorders | |
| KR20180058829A (ko) | Ezh2 억제제로 수모세포종을 치료하는 방법 | |
| EP3801528B1 (en) | Eaat2 activators and methods of using thereof | |
| WO2015083750A1 (ja) | 神経新生に関する化合物及び医薬組成物 | |
| CN108883088A (zh) | 利用色酮衍生物的上皮间质转化抑制活性的作为纤维化预防及治疗用药剂学组合物的新用途 | |
| US20180042905A1 (en) | Methods of treating hepatitis b virus | |
| JP2022529363A (ja) | Ｃｒｙａｂ凝集阻害剤である２５－ヒドロキシコレステロール（２５ｈｃ）は新規の老化細胞除去剤である | |
| JP2018515614A5 (enExample) | ||
| ES2928666T3 (es) | Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas | |
| JP2016537432A5 (enExample) | ||
| WO2015140799A1 (en) | Methods for improving cognitive function via modulation of quinone reductase 2 | |
| WO2015005491A1 (ja) | 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法 | |
| JP2022501390A (ja) | 化合物及びその用途 | |
| CN109956975A (zh) | 肝递送恩替卡韦前体药物核苷环磷酸酯化合物及应用 | |
| CN109180679B (zh) | 一类N-取代吡唑并[3,4-d]嘧啶酮类化合物及其制备方法和应用 | |
| WO2018043674A1 (ja) | 神経新生を活性化するための組成物 | |
| CN109666013A (zh) | 双哌啶取代的异黄酮化合物及其用途 | |
| WO2017080313A1 (en) | Tetrahydropalmatine derivative, its preparation method and use | |
| US20190083422A1 (en) | Sense-33 compositions and methods thereof for enhancing the expression and/or activity of nicotinic acetylcholine receptors | |
| WO2025102989A1 (zh) | 靶向O-GlcNAc糖苷水解酶抑制剂促进髓鞘再生 |